Bing

SEARCH HISTORY

Alnylam Pharmaceuticals (ALNY)- The company’s shares rose 2.5 pct. Exact Sciences Corp (EXAS)- The company’s stocks rallied 20.6% Tornier N.V. (TRNX)- The company’s shares advanced 0.9 pct. Celldex …
Fx Pips · 5/27/2015
Myriad Genetics (NASDAQ:MYGN)‘s stock had its “underperform” rating reissued by equities researchers at Credit Suisse in a research report issued on Thursday. Myriad Genetics (NASDAQ:MYGN) opened at 33.85 on Thursday. Myriad Genetics …
sleekmoney.com · 5/29/2015
Myriad Genetics (NASDAQ:MYGN)‘s stock had its “underperform” rating reiterated by analysts at Credit Suisse in a research report issued to clients and investors on Thursday. Several other analysts have also recently commented on the stock.
Ticker Report · 5/28/2015
More from Bing News
Myriad Genetics (NASDAQ:MYGN) opened at 33.95 on Thursday. Myriad Genetics has a 52-week low of $31.56 and a 52-week high of $40.50. The stock’s 50-day moving average is $34. and its 200-day moving average is $34.. The company has a market …
wkrb13.com · 5/30/2015
Quest Diagnostics Inc (DGX): DGX stock is down 1.5% today. Array Biopharma Inc (ARRY): ARRY stock is down 1.3% today. Myriad Genetics (MYGN): MYGN stock is down 1.2% today. For more information on the best stocks to buy right now, check …
Investor Place · 5/28/2015
SALT LAKE CITY, May 28, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, president of Myriad Genetics Laboratories, is scheduled to present at the Goldman …
Financial Content · 5/28/2015
Myriad Genetics
Myriad Genetics (NASDAQ:MYGN), a company whose shares are moving quickly ... or 6.7% below the average consensus analyst price target of $36.23. The stock should run into initial resistance at its 50-day moving average (MA) of $34.90 and …
Financial News Network Online · ByAdrienne Chilton · 5/27/2015
Dangerous stocks have misleading earnings and long growth appreciation periods implied in their market valuations. Most Attractive: Myriad Genetics Myriad Genetics (MYGN) offers investors a rare combination of growth and value. MYGN has grown …
Forbes · 2/12/2014
So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case. MYGN currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Yahoo Finance · 10/20/2014
On Tuesday, small cap cancer diagnostic stock Myriad Genetics, Inc (NASDAQ: MYGN) jumped 11.42% in one day, meaning its worth taking a closer look at the stock along with the performance of small cap cancer diagnostic stocks like Rosetta …
Smallcap Network · ByJohn Udovich · 2/20/2014